Close Menu

NEW YORK ─ Italian researchers are developing a photonic biosensor testing platform that they believe could prove especially useful for clinicians prescribing colorectal cancer therapies by eliminating time-consuming steps associated with traditional liquid biopsy testing technologies.

The test uses surface plasmon resonance imaging (SPRI) to detect circulating DNA RAS mutations in patients' blood that are associated with resistance to colorectal cancer treatments.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.